DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
NOVA-22007 is an investigational drug.
There have been 26 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2017.
The most common disease conditions in clinical trials are Disease, Diabetes Mellitus, and Schizophrenia. The leading clinical trial sponsors are Nova Scotia Health Authority, Canadian Institutes of Health Research (CIHR), and Canadian Network for Observational Drug Effect Studies, CNODES.
There are two US patents protecting this investigational drug and forty-three international patents.
Recent Clinical Trials for NOVA-22007
|The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome||David Tang||Phase 4|
|Psychological Therapy for Psychosis, Adverse Events, and Substance Misuse||Killam Laureates||N/A|
|Psychological Therapy for Psychosis, Adverse Events, and Substance Misuse||Queen Elizabeth II Health Sciences Centre Foundation||N/A|
Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|NOVA-22007||Start Trial||Fused bicyclic heteroaromatic derivatives as kinase inhibitors||UCB BIOPHARMA SPRL (Brussels, BY) KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (Leuven, BE)||Start Trial|
|NOVA-22007||Start Trial||Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof||University Health Network (Toronto, CA)||Start Trial|
|NOVA-22007||Start Trial||Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same||SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)||Start Trial|
|NOVA-22007||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|NOVA-22007||Start Trial||Salts of an epidermal growth factor receptor kinase inhibitor||Celgene CAR LLC (Pembroke, BM)||Start Trial|
|NOVA-22007||Start Trial||Methods of treating colorectal cancer||Nogra Pharma Limited (Dublin, IE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|NOVA-22007||European Patent Office||EP3157924||2034-06-17||Start Trial|
|NOVA-22007||United Kingdom||GB201410817||2034-06-17||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|